YOKNEAM, Israel, Dec. 18 -- OpusDent Ltd., a subsidiary of ESC Medical Systems Ltd., has received the approval of the US Food and Drug Administration to market its dental laser. The Opus 20 combines a CO2 and an erbium laser in one system, and can be used for a wide variety of dental procedures.
This FDA clearance is a significant step forward for OpusDent, said Yacha Sutton, president and CEO of ESC Medical Systems. Opus 20 joins the Novapulse suppressing CO2 laser and Opus 10 portable diode laser to complete OpusDent's FDA-cleared product portfolio and paves the way for immediate penetration of the US market.
One of the most popular attributes of the dental laser is its ability to allow painless drilling that requires little to no anesthesia, said ESC Medical Systems.